福瑞股份收盘下跌3.15%，滚动市盈率65.22倍，总市值85.05亿元

Core Insights - The company, Furuai Co., Ltd., closed at 31.93 yuan, down 3.15%, with a rolling PE ratio of 65.22 times and a total market value of 8.505 billion yuan [1][2] - The average PE ratio in the medical device industry is 44.72 times, with a median of 32.59 times, placing Furuai Co. at the 102nd position in the industry ranking [1][2] - As of the Q3 2024 report, 137 institutions hold shares in Furuai Co., with a total of 41.4368 million shares valued at 1.307 billion yuan [1] Company Overview - Furuai Co. specializes in the production and sales of drugs in the liver disease sector, development and sales of diagnostic equipment, and related medical services [1] - Key products include Fufang Bie Jia Soft Liver Tablets, FibroScan series liver fibrosis diagnostic instruments, FibroMeter blood test analysis tools, and FibroView data management software [1] - The company emphasizes building good public relations and actively participates in social welfare initiatives, having received multiple awards for its corporate social responsibility efforts [1] Financial Performance - For Q3 2024, the company reported revenue of 980 million yuan, a year-on-year increase of 21.42%, and a net profit of 102 million yuan, up 39.42%, with a gross margin of 76.50% [2] - The company's PE ratio (TTM) is 65.22, while the industry average is 44.72, indicating a higher valuation compared to peers [2]